Role for histone deacetylase 1 in human tumor cell proliferation

Molecular and Cellular Biology

Volumn 27, Issue 13, 2007, Pages 4784-4795

  Senese, Silvia ^a,b   Zaragoza, Katrin ^a   Minardi, Simone ^b   Muradore, Ivan ^a   Ronzoni, Simona ^a   Passafaro, Alfonso ^a   Bernard, Loris ^b   Draetta, Giulio F ^c   Alcalay, Myriam ^b   Seiser, Christian ^d   Chiocca, Susanna ^a,b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^c MERCK RESEARCH LABORATORIES   (United States)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; KNOCKOUT GENE; PRIORITY JOURNAL; RNA INTERFERENCE; TUMOR GROWTH;

ACETYLATION; CELL DEATH; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CLUSTER ANALYSIS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; G1 PHASE; G2 PHASE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HISTONES; HUMANS; NEOPLASMS; PHOSPHORYLATION; REPRESSOR PROTEINS; RNA, SMALL INTERFERING;

CAENORHABDITIS ELEGANS; DANIO RERIO; XENOPUS LAEVIS;

EID: 34347339526     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.00494-07     Document Type: Article

References (58)

1. Ahringer, J. 2000. NuRD and SIN3 histone deacetylase complexes in development. Trends Genet. 16:351-356.
2. Alcalay, M., N. Meani, V. Gelmetti, A. Fantozzi, M. Fagioli, A. Orleth, D. Riganelli, C. Sebastiani, E. Cappelli, C. Casciari, M. T. Sciurpi, A. R. Mariano, S. P. Minardi, L. Luzi, H. Muller, P. P. Di Fiore, G. Frosina, and P. G. Pelicci. 2003. Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J. Clin. Investig. 112:1751-1761.
3. Bartl, S., J. Taplick, G. Lagger, H. Khier, K. Kuchler, and C. Seiser. 1997. Identification of mouse histone deacetylase 1 as a growth factor-inducible gene. Mol. Cell. Biol. 17:5033-5043.
4. Bolden, J. E., M. J. Peart, and R. W. Johnstone. 2006. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5:769-784.
5. Choi, J. H., H. J. Kwon, B. I. Yoon, J. H. Kim, S. U. Han, H. J. Joo, and D. Y. Kim. 2001. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn. J. Cancer Res. 92:1300-1304.
6. Cobb, J., M. Miyaike, A. Kikuchi, and M. A. Handel. 1999. Meiotic events at the centromeric heterochromatin: histone H3 phosphorylation, topoisomerase II alpha localization and chromosome condensation. Chromosoma 108:412-425.
7. Cress, W. D., and E. Seto. 2000. Histone deacetylases, transcriptional con-trol, and cancer. J. Cell Physiol. 184:1-16.
8. David, G., G. M. Turner, Y. Yao, A. Protopopov, and R. A. DePinho. 2003. mSin3-associated protein, mSds3, is essential for pericentric heterochromatin formation and chromosome segregation in mammalian cells. Genes Dev. 17:2396-2405.
9. Ekwall, K., T. Olsson, B. M. Turner, G. Cranston, and R. C. Allshire. 1997. Transient inhibition of histone deacetylation alters the structural and functional imprint at fission yeast centromeres. Cell 91:1021-1032.
10. Finocchiaro, G., P. Parise, S. P. Minardi, M. Alcalay, and H. Muller. 2004. GenePicker: replicate analysis of Affymetrix gene expression microarrays. Bioinformatics 20:3670-3672.
11. Fischle, W., F. Dequiedt, M. J. Hendzel, M. G. Guenther, M. A. Lazar, W. Voelter, and E. Verdin. 2002. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell 9:45-57.
12. Gao, L., M. A. Cueto, F. Asselbergs, and P. Atadja. 2002. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. 277:25748-25755.
13. Glaser, K. B., J. Li, M. J. Staver, R. Q. Wei, D. H. Albert, and S. K. Davidsen. 2003. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem. Biophys. Res. Commun. 310:529-536.
14. Glaser, K. B., M. J. Staver, J. F. Waring, J. Stender, R. G. Ulrich, and S. K. Davidsen. 2003. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2:151-163.
15. Gregoretti, I. V., Y. M. Lee, and H. V. Goodson. 2004. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 338:17-31.
16. Grozinger, C. M., and S. L. Schreiber. 2002. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem. Biol. 9:3-16.
17. Gurley, L. R., R. A. Walters, and R. A. Tobey. 1973. Histone phosphorylation in late interphase and mitosis. Biochem. Biophys. Res. Commun. 50:744-750.
18. Halkidou, K., L. Gaughan, S. Cook, H. Y. Leung, D. E. Neal, and C. N. Robson. 2004. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59:177-189.
19. Hauser, C., B. Schuettengruber, S. Bartl, G. Lagger, and C. Seiser. 2002. Activation of the mouse histone deacetylase 1 gene by cooperative histone phosphorylation and acetylation. Mol. Cell. Biol. 22:7820-7830.
20. Henderson, C., and C. Brancolini. 2003. Apoptotic pathways activated by histone deacetylase inhibitors: implications for the drug-resistant phenotype. Drug Resist. Updates 6:247-256.
21. Henderson, C., M. Mizzau, G. Paroni, R. Maestro, C. Schneider, and C. Brancolini. 2003. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J. Biol. Chem. 278:12579-12589.
22. Hendzel, M. J., Y. Wei, M. A. Mancini, A. Van Hooser, T. Ranalli, B. R. Brinkley, D. P. Bazett-Jones, and C. D. Allis. 1997. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 106:348-360.
23. Hsu, J. Y., Z. W. Sun, X. Li, M. Reuben, K. Tatchell, D. K. Bishop, J. M. Grushcow, C. J. Brame, J. A. Caldwell, D. F. Hunt, R. Lin, M. M. Smith, and C. D. Allis. 2000. Mitotic phosphorylation of histone H3 is governed by Ipl1/aurora kinase and Glc7/PP1 phosphatase in budding yeast and nematodes. Cell 102:279-291.
24. Huang, B. H., M. Laban, C. H. Leung, L. Lee, C. K. Lee, M. Salto-Tellez, G. C. Raju, and S. C. Hooi. 2005. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ. 12:395-404.
25. Hubbert, C., A. Guardiola, R. Shao, Y. Kawaguchi, A. Ito, A. Nixon, M. Yoshida, X. F. Wang, and T. P. Yao. 2002. HDAC6 is a microtubule-associated deacetylase. Nature 417:455-458.
26. Humphrey, G. W., Y. Wang, V. R. Russanova, T. Hirai, J. Qin, Y. Nakatani, and B. H. Howard. 2001. Stable histone deacetylase complexes distinguished by the presence of SANT domain proteins CoREST/kiaa0071 and Mta-L1. J. Biol. Chem. 276:6817-6824.
27. Hutchins, J. R., and P. R. Clarke. 2004. Many fingers on the mitotic trigger: post-translational regulation of the Cdc25C phosphatase. Cell Cycle 3:41-45.
28. Ito, A., Y. Kawaguchi, C. H. Lai, J. J. Kovacs, Y. Higashimoto, E. Appella, and T. P. Yao. 2002. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 21:6236-6245.
29. Johnstone, R. W. 2002. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1:287-299.
30. Johnstone, R. W., and J. D. Licht. 2003. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4:13-18.
31. Kartmann, B., and D. Roth. 2001. Novel roles for mammalian septins: from vesicle trafficking to oncogenesis. J. Cell Sci. 114:839-844.
32. Kawai, H., H. Li, S. Avraham, S. Jiang, and H. K. Avraham. 2003. Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. Int. J. Cancer 107:353-358.
33. Khochbin, S., A. Verdel, C. Lemercier, and D. Seigneurin-Berny. 2001. Functional significance of histone deacetylase diversity. Curr. Opin. Genet. Dev. 11:162-166.
34. Kim, J. H., Y. K. Choi, H. J. Kwon, H. K. Yang, J. H. Choi, and D. Y. Kim. 2004. Downregulation of gelsolin and retinoic acid receptor beta expression in gastric cancer tissues through histone deacetylase 1. J. Gastroenterol. Hepatol. 19:218-224.
35. Kramer, O. H., P. Zhu, H. P. Ostendorff, M. Golebiewski, J. Tiefenbach, M. A. Peters, B. Brill, B. Groner, I. Bach, T. Heinzel, and M. Gottlicher. 2003. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J. 22:3411-3420.
36. Lagger, G., A. Doetzlhofer, B. Schuettengruber, E. Haidweger, E. Simboeck, J. Tischler, S. Chiocca, G. Suske, H. Rotheneder, E. Wintersberger, and C. Seiser. 2003. The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene. Mol. Cell. Biol. 23:2669-2679.
37. Lagger, G., D. O'Carroll, M. Rembold, H. Khier, J. Tischler, G. Weitzer, B. Schuettengruber, C. Hauser, R. Brunmeir, T. Jenuwein, and C. Seiser. 2002. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 21:2672-2681.
38. Li, Y., G. D. Kao, B. A. Garcia, J. Shabanowitz, D. F. Hunt, J. Qin, C. Phelan, and M. A. Lazar. 2006. A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity. Genes Dev. 20:2566-2579.
39. Luo, J., A. Y. Nikolaev, S. Imai, D. Chen, F. Su, A. Shiloh, L. Guarente, and W. Gu. 2001. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107:137-148.
40. Marks, P., R. A. Rifkind, V. M. Richon, R. Breslow, T. Miller, and W. K. Kelly. 2001. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1:194-202.
41. Marks, P. A. 2007. Discovery and development of SAHA as an anticancer agent. Oncogene 26:1351-1356.
42. Ng, H. H., and A. Bird. 2000. Histone deacetylases: silencers for hire. Trends Biochem. Sci. 25:121-126.
43. Ono, R., T. Taki, T. Taketani, H. Kawaguchi, M. Taniwaki, T. Okamura, K. Kawa, R. Hanada, M. Kobayashi, and Y. Hayashi. 2002. SEPTIN6, a human homologue to mouse Septin6, is fused to MLL in infant acute myeloid leukemia with complex chromosomal abnormalities involving 11q23 and Xq24. Cancer Res. 62:333-337.
44. Patra, S. K., A. Patra, and R. Dahiya. 2001. Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem. Biophys. Res. Commun. 287:705-713.
45. Paulson, J. R., and S. S. Taylor. 1982. Phosphorylation of histones 1 and 3 and nonhistone high mobility group 14 by an endogenous kinase in HeLa metaphase chromosomes. J. Biol. Chem. 257:6064-6072.
46. Peart, M. J., G. K. Smyth, R. K. van Laar, D. D. Bowtell, V. M. Richon, P. A. Marks, A. J. Holloway, and R. W. Johnstone. 2005. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA 102:3697-3702.
47. Richon, V. M., T. W. Sandhoff, R. A. Rifkind, and P. A. Marks. 2000. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA 97:10014-10019.
48. Richon, V. M., Y. Webb, R. Merger, T. Sheppard, B. Jursic, L. Ngo, F. Civoli, R. Breslow, R. A. Rifkind, and P. A. Marks. 1996. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl. Acad. Sci. USA 93:5705-5708.
49. Sasaki, S., L. A. Lesoon-Wood, A. Dey, T. Kuwata, B. D. Weintraub, G. Humphrey, W. M. Yang, E. Seto, P. M. Yen, B. H. Howard, and K. Ozato. 1999. Ligand-induced recruitment of a histone deacetylase in the negative-feedback regulation of the thyrotropin beta gene. EMBO J. 18:5389-5398.
50. Taddei, A., C. Maison, D. Roche, and G. Almouzni. 2001. Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases. Nat. Cell Biol. 3:114-120.
51. Vance, K. W., S. Carreira, G. Brosch, and C. R. Goding. 2005. Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas. Cancer Res. 65:2260-2268.
52. Vaziri, H., S. K. Dessain, E. Ng Eaton, S. I. Imai, R. A. Frye, T. K. Pandita, L. Guarente, and R. A. Weinberg. 2001. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107:149-159.
53. Weiss, R. H. 2003. p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 4:425-429.
54. Wilson, A. J., D. S. Byun, N. Popova, L. B. Murray, K. L'Italien, Y. Sowa, D. Arango, A. Velcich, L. H. Augenlicht, and J. M. Mariadason. 2006. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J. Biol. Chem. 281:13548-13558.
55. Xu, W. S., G. Perez, L. Ngo, C. Y. Gui, and P. A. Marks. 2005. Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. Cancer Res. 65:7832-7839.
56. Yang, X. J. 2005. Multisite protein modification and intramolecular signaling. Oncogene 24:1653-1662.
57. Zhang, Y., N. Li, C. Caron, G. Matthias, D. Hess, S. Khochbin, and P. Matthias. 2003. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J. 22:1168-1179.
58. Zhu, P., E. Martin, J. Mengwasser, P. Schlag, K. P. Janssen, and M. Gottlicher. 2004. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5:455-463.